NeuroOne preliminarily reports FY2026 revenue of $10.5M and record $4.5M purchase order

NEUROONE MEDICAL TECHNOLOGIES Corp

Preliminary FY2026 revenue was approximately $10.5 million, at the top of guidance range of $9.2 million to $10.5 million, up 15.6% year-over-year.
Preliminary fiscal Q4 2026 product revenue was approximately $3.8 million, up 38.4% from approximately $2.7 million in Q4 fiscal 2025.
NeuroOne received a record $4.5 million purchase order in September 2026; about $1.0 million shipped by September 30, 2026.
Remaining $3.6 million from that order is expected to ship in Q1 and Q2 fiscal 2027; open purchase orders totaled $5.4 million as of Sept 30, 2026.
CEO Dave Rosa said fiscal 2026 product orders rose 24.2%, with growth drivers including trigeminal neuralgia system commercialization and international expansion.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.